Dataset Information


Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.

ABSTRACT: Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established preclinical taxane-platin-chemoresistance models and identified a 35-gene resistance signature, which was associated with poor recurrence-free survival in neoadjuvant-treated NSCLC patients and included upregulation of the JumonjiC lysine demethylase KDM3B. In fact, multi-drug-resistant cells progressively increased the expression of many JumonjiC demethylases, had altered histone methylation, and, importantly, showed hypersensitivity to JumonjiC inhibitors in vitro and in vivo. Increasing taxane-platin resistance in progressive cell line series was accompanied by progressive sensitization to JIB-04 and GSK-J4. These JumonjiC inhibitors partly reversed deregulated transcriptional programs, prevented the emergence of drug-tolerant colonies from chemo-naive cells, and synergized with standard chemotherapy in vitro and in vivo. Our findings reveal JumonjiC inhibitors as promising therapies for targeting taxane-platin-chemoresistant NSCLCs.


PROVIDER: S-EPMC5531293 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-12-31 | GSE77209 | GEO
2017-05-23 | GSE81688 | GEO
2017-05-23 | GSE81687 | GEO
| PRJNA322313 | ENA
2011-01-01 | S-EPMC3205057 | BioStudies
| PRJNA309709 | ENA
| PRJNA322314 | ENA
| PRJNA322315 | ENA
| S-EPMC2671397 | BioStudies
2019-01-01 | S-EPMC6627323 | BioStudies